Capricor’s BLA for Deramiocel was granted Priority Review in March 2025 and was supported by data from the HOPE-2 trial, its open-label extension (OLE), and natural history comparisons from FDA-funded ...

Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). Such investors are ...

Capricor TherapeuticsCAPR just hit that mark, with a jump from 69 to 86 Thursday. Please watch the video at Investors.com - ...

Capricor (CAPR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

Fintel reports that on June 26, 2025, B. Riley Securities initiated coverage of Capricor Therapeutics (NasdaqCM:CAPR) with a Buy recommendation. Analyst Price Forecast Suggests 327.54% Upside As of ...

Capricor on Tuesday disclosed that the FDA has indicated that no AdCom is necessary for deramiocel’s Biologics License Application, and an in-person late-cycle review meeting is scheduled for ...

Capricor Therapeutics CAPR shares ended the last trading session 20.4% higher at $9.25. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

Capricor Therapeutics said on Tuesday the U.S. Food and Drug Administration will not convene its panel of outside experts before deciding on the company's cell therapy for a heart condition associated ...

Capricor is also harnessing the power of its exosome technology, using its proprietary StealthX™ platform in preclinical development focused on the areas of vaccinology, targeted delivery of ...

Capricor Therapeutics is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases.